✦ LIBER ✦

Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis

✍ Scribed by O’Day, Ken; Meyer, Kellie; Miller, Ross M.; Agarwal, Sonalee; Franklin, Meg

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PND23 Economic Evaluation of Natalizumab

✍ S.T. Alexopoulos; B. Deniz; A.R. Walker; R. Arnold; D. Bates 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB

Cost minimisation analysis of fingolimod

✍ Crespo, C.; Izquierdo, G.; García-Ruiz, A.; Granell, M.; Brosa, M. 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 480 KB

Cost-effectiveness of fingolimod versus

✍ Lee, Soyon; Baxter, Daniel C.; Limone, Brendan; Roberts, Matthew S.; Coleman, Cr 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 382 KB

PND9 THE COST-EFFECTIVENESS OF NATALIZUM

✍ K Meyer; E Chiao 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

Cost effectiveness and budget impact of

✍ Chiao, Evelyn; Meyer, Kellie 📂 Article 📅 2009 🏛 Informa plc 🌐 English ⚖ 170 KB

PND38 Cost Minimization Analysis of Fing

✍ Crespo, C.; Izquierdo, G.; García-Ruiz, A.; Granell, M.; Brosa, M. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB